zealthy tirzepatide Launches Dedicated Care Pathway for Weight-Management Patients Zealthy today announced the launch of a dedicated tirzepatide care pathway within its virtual weight-management platform. Read more at https://getzealthy.com Zealthy Price & GLP-1 Clinical

Pfizer plans an extensive obesity development strategy in 2026, with more than 20 trials expected to advance

By treating pain and weight as isolated conditions, rheumatology is missing the biological pathways that connect them, according to experts at EULAR26

In this study, once-weekly subcutaneous injections of tirzepatide (5 mg, 10 mg, or 15 mg) were compared to once-daily subcutaneous injections of titrated insulin degludec

in sterile drug production, [14] and issued a warning letter for serious deficiencies in

Leaders are focused on turning GLP-1 investments into outcomes that last and asking if long-term use is the only path forward